skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Mechanism of the inhibitory effect of ghrelin in sepsis

Review

(2103) Views  (796) Full article downloads

Authors: Asha Jacob, Rongqian Wu, Mian Zhou, et al

Published Date February 2010 Volume 2010:2 Pages 33 - 38
DOI: http://dx.doi.org/10.2147/HMER.S7187

Asha Jacob, Rongqian Wu, Mian Zhou, Gene F Coppa, Ping Wang

Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center, and The Feinstein Institute for Medical Research, Manhasset, NY, USA

Abstract: Sepsis and septic shock are the leading causes of death in intensive care units. Approximately 40%–70% of the mortality is associated with severe sepsis and septic shock. Systemic antibiotic usage, surgical intervention, aggressive fluid resuscitation and careful monitoring are common measures currently used to treat sepsis. Despite the advances in the understanding of the pathophysiology of sepsis, very little progress has been made towards therapeutic interventions. Recently we have shown that ghrelin, a stomach-derived peptide which is an endogenous ligand for the growth hormone secretagogue receptor (GHSR-1a), is beneficial in attenuating the inflammatory response, organ injury and mortality in an experimental model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). In this review, we describe the mechanism of action of ghrelin in sepsis, highlight the role ghrelin plays in attenuating the hepatic dysfunction induced by sepsis and septic shock and suggest in developing ghrelin as a potential therapy for sepsis.

Keywords: ghrelin, sepsis, inhibition septic shock, GHSR-1a, cecal ligation








Readers of this article also read:

Bortezomib in the management of multiple myeloma
Cyclic AMP-guanine exchange factor activation inhibits JNK-dependent lipopolysaccharide-induced apoptosis in rat hepatocytes
Insulin-like growth factor binding protein-3 is required for the regulation of rat oval cell proliferation and differentiation in the 2AAF/PHX model
Liver stiffness: a novel parameter for the diagnosis of liver disease
Optimal management of hepatorenal syndrome in patients with cirrhosis
A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection
Update on new approaches in the management of hepatocellular carcinoma
Pathogenesis and management of alcoholic liver cirrhosis: a review
Corrigendum
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio